Uncovering Active Ingredients and Mechanisms of Spica Prunellae in the Treatment of Colon Adenocarcinoma: A Study Based on Network Pharmacology and Bioinformatics

Author:

Lei Yan1,Yuan Hao2,Gai Liyue3,Wu Xuelian3,Luo Zhixiao4

Affiliation:

1. Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

2. BGI Education Center, University of Chinese Academy of Sciences, Shenzhen, 518083, China

3. College of Medical Science, China Three Gorges University, Yichang 443002, China

4. Health Management Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

Abstract

Background: As a well-known herb used in the treatment of colon adenocarcinoma (COAD), Spica Prunellae (SP) shows favorable clinical effect and safety in China for many years, but its active ingredients and therapeutic mechanisms against COAD remain poorly understood. Therefore, this study aims to uncover active ingredients and mechanisms of SP in the treatment of COAD using a combined approach of network pharmacology and bioinformatics. Methods: A comprehensive approach mainly comprised of target prediction, network construction, pathway and functional enrichment analysis, and hub genes verification was adopted in the current study. Results: We collected 102 compounds-related genes and 3549 differently expressed genes (DEGs) following treatment with SP, and 64 disease-drug target genes between them were recognized. In addition, a total of 25 active ingredients in SP were identified. Pathway and functional enrichment analyses suggested that the mechanisms of SP against COAD might be to induce apoptosis of colon cancer cells by regulating PI3K-Akt and TNF signaling pathways. Recognition of hub genes and core functional modules was performed by constructing protein-protein interaction (PPI) network, from which TP53, MYC, MAPK8 and CASP3 were found as the hub target genes that might play an important part in therapy for COAD. Subsequently we further compared the differential expression level and assessed the prognostic value of these four hub genes. These result of verification suggested that SP exerted therapeutic effects against COAD via a PPI network involving TP53, MYC, MAPK8 and CASP3. Conclusion: In this study, active ingredients and mechanisms of SP in the treatment of COAD were systematically discussed, which provided the foundation for further experimental studies and might act to promote its appropriate clinical application.

Publisher

Bentham Science Publishers Ltd.

Subject

Organic Chemistry,Computer Science Applications,Drug Discovery,General Medicine

Reference55 articles.

1. Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2018. CA Cancer J Clin 2018,68(1),7-30

2. Allemani C.; Matsuda T.; Di Carlo V.; Harewood R.; Matz M.; Nikšić M.; Bonaventure A.; Valkov M.; Johnson C.J.; Estève J.; Ogunbiyi O.J.; Azevedo E.; Silva, G.; Chen, W.Q.; Eser, S.; Engholm, G.; Stiller, C.A.; Monnereau, A.; Woods, R.R.; Visser, O.; Lim, G.H.; Aitken, J.; Weir, H.K.; Coleman, M.P.; Group, C.W. CONCORD Working Group. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018,391(10125),1023-1075

3. Chen W.; Zheng R.; Zeng H.; Zhang S.; The incidence and mortality of major cancers in China, 2012. Chin J Cancer 2016,35(1),73

4. Benson A.B.; Venook A.P.; Al-Hawary M.M.; Cederquist L.; Chen Y.J.; Ciombor K.K.; Cohen S.; Cooper H.S.; Deming D.; Engstrom P.F.; Garrido-Laguna I.; Grem J.L.; Grothey A.; Hochster H.S.; Hoffe S.; Hunt S.; Kamel A.; Kirilcuk N.; Krishnamurthi S.; Messersmith W.A.; Meyerhardt J.; Miller E.D.; Mulcahy M.F.; Murphy J.D.; Nurkin S.; Saltz L.; Sharma S.; Shibata D.; Skibber J.M.; Sofocleous C.T.; Stoffel E.M.; Stotsky-Himelfarb E.; Willett C.G.; Wuthrick E.; Gregory K.M.; Freedman-Cass D.A.; NCCN guidelines insights: colon cancer, version 2.2018. J Natl Compr Canc Netw 2018,16(4),359-369

5. Watanabe T.; Muro K.; Ajioka Y.; Hashiguchi Y.; Ito Y.; Saito Y.; Hamaguchi T.; Ishida H.; Ishiguro M.; Ishihara S.; Kanemitsu Y.; Kawano H.; Kinugasa Y.; Kokudo N.; Murofushi K.; Nakajima T.; Oka S.; Sakai Y.; Tsuji A.; Uehara K.; Ueno H.; Yamazaki K.; Yoshida M.; Yoshino T.; Boku N.; Fujimori T.; Itabashi M.; Koinuma N.; Morita T.; Nishimura G.; Sakata Y.; Shimada Y.; Takahashi K.; Tanaka S.; Tsuruta O.; Yamaguchi T.; Yamaguchi N.; Tanaka T.; Kotake K.; Sugihara K.; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 2018,23(1),1-34

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3